06/18/2026
A meaningful step forward for the GM2 community!
We're glad to share this update from our partners at Azafaros, newly published Phase 2 data for nizubaglustat, demonstrating encouraging safety and evidence of reduced disease progression and seizure burden.
Read More: https://bit.ly/4oUrqHT
If you have questions about what this means for the NTSAD community, we're here for you. Feel free to reach out to [email protected] with any questions.